Posts Tagged 'janssen pharmaceuticals'

For Some Risperdal Users, Side Effect Reminder is as Close as Nearest Mirror

gynocomastia lawsuits continue over risperdalFormer users of Janssen Pharmaceuticals’ antipsychotic drug Risperdal continue to feel the impact of a long-undisclosed potential side effect of the medication. The drug is intended to treat schizophrenia and bipolar disorder, however, since its release, multiple misrepresentations about Risperdal have been made to patients and their doctors. In perhaps the most glaring example, some males who have used the drug have developed a disorder called gynecomastia. The condition causes them to ...

continue reading...

Judge Shocks Both Sides with Move to Dismiss Risperdal Case

judge dismisses janssen lawsuit mid-trialMost of the time, a judge’s actions in a case are somewhat expected by at least one side. A plaintiff or defendant might argue for a particular action and the outcome is based on either the success or failure of that argument. However, every so often a judge does something that catches both sides off guard.

Such was the case in Philadelphia when Philadelphia Court of Common Pleas Judge Sean Kennedy dismissed plaintiff ...

continue reading...

Xarelto: Higher Risk Same Reward?

xarelto may be no more beneficial than warfarin and be more dangerousOver 1,200 Xarelto lawsuits are pending in a multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana. Xarelto plaintiffs allege that the anticoagulant drug’s manufacturers, including Bayer HealthCare Pharmaceuticals and Johnson & Johnson’s Janssen Pharmaceutical, did not provide patients and doctors with adequate warning about Xarelto’s severe bleeding risks.

Approved by the U.S. Food and Drug Administration (FDA) in 2011 ...

continue reading...

New Study: Xarelto No Safer than Warfarin in Elderly

xarelto may not be any safer than warfarin in elderly patientsJanssen Pharmaceuticals and Bayer have long insisted their blood-thinning drug Xarelto is a safer, more reliable alternative to the decades-old warfarin. However, a new study recently published in the American Heart Association’s journal Circulation suggests the popular “new-age” anticoagulant may be no safer than warfarin in terms of bleeding in elderly patients.

Xarelto was approved by the U.S. Food and Drug Administration in 2011 for ...

continue reading...

Invokana Maker Counters with Own SGLT2 Inhibitor Study

invokana issues report rebuttalAmid recent research linking sodium-glucose cotransporter-2 (SGLT2) inhibitors to diabetic ketoacidosis, Invokana maker Janssen Pharmaceutica has countered with its own report on the new diabetic drug. The study, published in late July by the journal Diabetes Care, claims that incidents of the potentially fatal blood condition are “rare.”

SGLT2 inhibitors are a relatively new class of type 2 diabetes drugs. They work by reducing the amount of glucose reabsorbed in the kidneys ...

continue reading...

New Thoughts on SGLT2 Inhibitor–Induced Diabetic Ketoacidosis

questions remain about sglt2 inhibitorsWhile sodium-glucose cotransporter-2 (SGLT2) inhibitors draw praise for their weight-loss and blood pressure reduction benefits, medical experts continue to puzzle over their more immediate metabolic and immune system effects. Specifically, researchers are worried about their possible link to diabetic ketoacidosis, a potentially fatal condition caused by excess blood acids, or ketones. In an article published by the Journal of Diabetes Investigation, two Japanese researchers provide a possible explanation for how continue reading...

Page 1 of 2 12